Now Available once-daily dosing.

Average daily dose of AUSTEDO in clinical trials was >36 mg/day1,2

12 mg
18 mg
24 mg
30 mg
36 mg
42 mg
48 mg

Total Daily Dosage

 

More than half of patients were between 36 mg/day and 48 mg/day at the end of the long-term study2

Patients in the pivotal and long-term studies received the AUSTEDO BID formulation.1,2

AUSTEDO XR: new once-daily dosing1

Start treatment at 12 mg/day

Blue arrow pointing right

Increase by 6 mg/day weekly1*

12 mg

once daily

Q12

Week 1

18 mg

once daily

Q6

Q12

Week 2

24 mg

once daily

Q24

Week 3

30 mg

once daily

Q6

Q24

Week 4

36 mg

once daily

Q12

Q24

Week 5

Average dose in trials was >36 mg/day1,2

42 mg

once daily

Q6

Q12

Q24

Week 6

48 mg

once daily

Q24

Q24

Week 7

*48 mg/day maximum dose.1


Available in 6 mg, 12 mg, and 24 mg extended-release tablets1

Q6

6 mg

Q12

12 mg

Q24

24 mg

Tablets not shown at actual size.

AUSTEDO XR can be taken with or without food1

Swallow AUSTEDO® XR (deutetrabenazine) extended-release tablets whole. Do not chew, crush, or break tablets.1

REFERENCES: 1. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc. 2. Hauser RA, Barkay H, Fernandez HH, et al. Long-term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-year, open-label extension study. Front Neurol. 2022;13:773999. doi:10.3389/fneur.2022.773999